An Anti-Cancer Immunoadhesin Made in Plants
An Anti-Cancer Immunoadhesin Made in Plants
批准号:
7612604
负责人:
KEITH WYCOFF
金额:
$15.95万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-22 至 2009-05-31
关键词:
AdultAmino AcidsAntibody FormationAntineoplastic AgentsBindingBioreactorsBlood VesselsCellsConditionDevelopmentDisseminated Malignant NeoplasmDoseEffector CellEndothelial CellsEngineeringFoodFood ChainFood SupplyGenetically Modified AnimalsGoalsGrowthHumanImmuneImmunoglobulin GLifeMaizeMalignant NeoplasmsMammalian CellMediatingModelingModificationNeoplasm MetastasisNeoplasms in Vascular TissueNude MiceOxygenPhasePlantsPrionsProductionProteinsPublic HealthRangeRecombinant ProteinsReportingResearchSafetySeedsSurfaceSystemTestingTherapeuticTobaccoTransgenic PlantsTumor Cell LineVariantVirusXenograft procedureZea maysangiogenesisanthrax toxinantibody-dependent cell cytotoxicitycancer therapycostdosagefeedingimprovedmouse modelnovelprotein expressionreceptorreceptor bindingtherapeutic proteintoe corntumortumor endothelial marker 8tumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The growth and metastasis of tumors depends, to a large extent, on the development of new blood vessels to supply food and oxygen to rapidly growing and dividing cells. Proteins involved in angiogenesis are attractive targets for new cancer therapeutics. One protein in particular, tumor endothelial marker 8 (TEM8), appears to be expressed exclusively, in adults, in the endothelial cells lining tumor blood vessels. A recent report found that a fusion of TEM8 and the Fc portion of IgG (TEM8-Fc) was a potent anti-cancer agent in a mouse model against a range of human tumor types. The overall goal of this Phase I project is to produce, using a rapid and transient plant expression system, forms of TEM8-Fc that will have enhanced binding to certain receptors on immune effector cells. Improvements in receptor binding will be achieved through both glycoform and amino acid engineering of the recombinant protein. We will then test the hypothesis that the anti-tumor activity of TEM8-Fc is related to its ability to mediate antibody dependent cellular cytotoxicity (ADCC) of cells expressing surface TEM8. Comparisons of ADCC activity will be followed by comparisons of anti-tumor activity in a nude mouse xenotransplantation model. Transgenic plants are a promising platform for the large-scale production of antibodies and other therapeutic proteins for treating serious and life-threatening conditions, including cancer. The advantages of using plants, rather than genetically modified animal cells in bioreactors, include very low cost of goods, and safety, due to the inability of plants to be infected with mammalian viruses and prions. Production in tobacco, a plant not used in the human food chain, avoids concerns about adventitious presence of therapeutic proteins in food or feed. In addition, the amount of protein that can be produced per acre with tobacco far exceeds what is possible with a seed crop like corn. Costs of purification, however, are similar to that of proteins produced in mammalian cell culture. The long-term goal is to develop TEM8-Fc into a highly effective, safe and economical treatment for a wide range of metastatic cancers. PUBLIC HEALTH RELEVANCE: New and more effective therapies for cancer are needed. This project would examine the mechanism of action of a novel recombinant protein that inhibits angiogenesis and growth of tumors, and should identify modifications to the protein that will make it even more effective at lower doses. Expression of this protein in plants will allow highly economical, large scale and safe production, making cancer therapy using dosages of a gram or greater of this recombinant protein much more available.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
-
批准号:10766626
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2023
-
负责人:KEITH WYCOFF
-
依托单位:
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
-
批准号:10219129
-
项目类别:
-
资助金额:$18.17万
-
财政年份:2020
-
负责人:KEITH WYCOFF
-
依托单位:
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening
-
批准号:9908223
-
项目类别:
-
资助金额:$29.86万
-
财政年份:2020
-
负责人:KEITH WYCOFF
-
依托单位:
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
-
批准号:10082224
-
项目类别:
-
资助金额:$26.29万
-
财政年份:2020
-
负责人:KEITH WYCOFF
-
依托单位:
A mucosally targeted MERS-CoV vaccine produced in plants
-
批准号:9141182
-
项目类别:
-
资助金额:$23.65万
-
财政年份:2017
-
负责人:KEITH WYCOFF
-
依托单位:
Exploiting Superinfection Exclusion To Express Polyclonal Antibodies In Plants
-
批准号:8781667
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
A MERS-CoV Receptor Decoy
-
批准号:8780733
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
A MERS-CoV Receptor Decoy
-
批准号:8981265
-
项目类别:
-
资助金额:$80.18万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
Targeted mutagenesis of plant genes by the CRISPR/Cas system
-
批准号:8713873
-
项目类别:
-
资助金额:$22.41万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
A MERS-CoV Receptor Decoy
-
批准号:9127085
-
项目类别:
-
资助金额:$77.34万
-
财政年份:2014
-
负责人:KEITH WYCOFF
-
依托单位:
Chimeric IgG/A Tumor Immunotherapy
-
批准号:8522804
-
项目类别:
-
资助金额:$27.68万
-
财政年份:2013
-
负责人:KEITH WYCOFF
-
依托单位:
Phase I clinical trial of an immunoadhesin antitoxin for anthrax
-
批准号:8469692
-
项目类别:
-
资助金额:$18.78万
-
财政年份:2013
-
负责人:KEITH WYCOFF
-
依托单位:
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
-
批准号:8450067
-
项目类别:
-
资助金额:$71.51万
-
财政年份:2012
-
负责人:KEITH WYCOFF
-
依托单位:
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
-
批准号:8268899
-
项目类别:
-
资助金额:$123.08万
-
财政年份:2012
-
负责人:KEITH WYCOFF
-
依托单位:
An immunoadhesin for treatment of hypercholesterolemia
-
批准号:8311591
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2012
-
负责人:KEITH WYCOFF
-
依托单位:
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
-
批准号:8076969
-
项目类别:
-
资助金额:$157.85万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
Plant-Made Nanobodies for Botulism Treatment
-
批准号:8058704
-
项目类别:
-
资助金额:$23.68万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
-
批准号:8461222
-
项目类别:
-
资助金额:$114.51万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
-
批准号:8262149
-
项目类别:
-
资助金额:$116.61万
-
财政年份:2011
-
负责人:KEITH WYCOFF
-
依托单位:
An Immunoadhesin Therapy for Inhalational Anthrax
-
批准号:7645285
-
项目类别:
-
资助金额:$134.54万
-
财政年份:2009
-
负责人:KEITH WYCOFF
-
依托单位:
海外基金